White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network

Annals of Neurology

Volumn 79, Issue 6, 2016, Pages 929-939

  Lee, Seonjoo ^a,b   Viqar, Fawad ^a,c   Zimmerman, Molly E ^c,d   Narkhede, Atul ^a   Tosto, Giuseppe ^a,e   Benzinger, Tammie L S ^f   Marcus, Daniel S ^f   Fagan, Anne M ^g   Goate, Alison ^h   Fox, Nick C ⁱ   Cairns, Nigel J ^g   Holtzman, David M ^g   Buckles, Virginia ^g   Ghetti, Bernardino ^j   McDade, Eric ^g   Martins, Ralph N ^k   Saykin, Andrew J ^j   Masters, Colin L ^l   Ringman, John M ^m   Ryan, Natalie S ⁱ   Förster, Stefan ⁿ   Laske, Christoph ^o   Schofield, Peter R ^p   Sperling, Reisa A ^q   Salloway, Stephen ^r   Correia, Stephen ^r   Jack, Clifford ^s   Weiner, Michael ^t   Bateman, Randall J ^g   Morris, John C ^g   Mayeux, Richard ^a,e,u   Brickman, Adam M ^a,e,u   more..

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c FORDHAM UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Department of Medicine   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j INDIANA UNIVERSITY   (United States)

^k EDITH COWAN UNIVERSITY   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY OF TÜBINGEN   (Germany)

^p UNIVERSITY OF NEW SOUTH WALES   (Australia)

^q BRIGHAM AND WOMEN S HOSPITAL   (United States)

^r BROWN UNIVERSITY   (United States)

^s MAYO CLINIC   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u Vagelos College of Physicians and Surgeons   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 2; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; ONSET AGE; PARIETAL LOBE; PRIORITY JOURNAL; WHITE MATTER HYPERINTENSITY; WHITE MATTER LESION; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MULTICENTER STUDY; NEUROIMAGING; PATHOLOGY; WHITE MATTER; YOUNG ADULT;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; PEPTIDE FRAGMENTS; PRESENILIN-1; PRESENILIN-2; TAU PROTEINS; WHITE MATTER; YOUNG ADULT;

EID: 84971222625     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24647     Document Type: Article

References (51)

1. Debette S, Markus HS,. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010; 341: c3666.
2. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S,. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 2015; 4: 001140.
3. Brickman AM,. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep 2013; 13: 415.
4. Jack CR, Jr., Knopman DS, Jagust WJ, et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
5. Lindemer ER, Salat DH, Smith EE, et al.,; Alzheimer's Disease Neuroimaging Initiative. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters. Neurobiol Aging 2015; 6: 2447-2457.
6. Brickman AM, Provenzano FA, Muraskin J, et al., Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 2012; 69: 1621-1627.
7. Zlokovic BV,. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738.
8. White L,. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis 2009; 18: 713-725.
9. Schneider JA, Arvanitakis Z, Bang W, Bennett DA,. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204.
10. Cairns NJ, Perrin RJ, Franklin EE, et al., Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 2015; 35: 390-400.
11. Bateman RJ, Xiong C, Benzinger TL, et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
12. Ryman DC, Acosta-Baena N, Aisen PS, et al., Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014; 83: 253-260.
13. Morris JC, Aisen PS, Bateman RJ, et al., Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012; 2: 975-984.
14. Morris JC, Ernesto C, Schafer K, et al., Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997; 48: 1508-1510.
15. Jack CR, Jr., Bernstein MA, Borowski BJ, et al., Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010; 6: 212-220.
16. Brickman AM, Zahodne LB, Guzman VA, et al., Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging 2015; 36: 27-32.
17. Knudsen KA, Rosand J, Karluk D, Greenberg SM,. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56: 537-539.
18. McZgee VE, Carleton WT,. Piecewise regression. J Am Stat Assoc 1970; 65: 1109-1124.
19. Kim HJ, Yu B, Feuer EJ,. Selecting the number of change-points in segmented line regression. Stat Sin 2009; 19: 597-609.
20. Piepho HP, Ogutu JO,. Inference for the break point in segmented regression with application to longitudinal data. Biometr J 2003; 45: 591-601.
21. Cleveland WS,. Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 829-836.
22. Burbridge JB, Magee L, Robb AL,. Alternative transformations to handle extreme values of the dependent variable. J Am Stat Assoc 1988; 83: 123-127.
23. Prins ND, Scheltens P,. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 2015; 11: 157-165.
24. Brickman AM, Guzman VA, Gonzalez-Castellon M, et al., Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett 2015; 592: 54-58.
25. Grimmer T, Faust M, Auer F, et al., White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 2012; 33: 2766-2773.
26. Zhou Y, Yu F, Duong TQ,. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients. J Magn Reson Imaging 2015; 41: 102-109.
27. Vemuri P, Lesnick TG, Przybelski SA, et al., Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 2015; 138 (pt 3): 761-771.
28. Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM,; Alzheimer's Disease Neuroimaging Initiative. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement 2015; 11: 1510-1519.
29. Erten-Lyons D, Woltjer R, Kaye J, et al., Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013; 81: 977-983.
30. Shim YS, Yang DW, Roe CM, et al., Pathological correlates of white matter hyperintensities on magnetic resonance imaging. Dement Geriatr Cogn Disord 2015; 39: 92-104.
31. Verhaaren BF, Debette S, Bis JC, et al., Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet 2015; 8: 398-409.
32. Ryan NS, Biessels GJ, Kim L, et al., Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiol Aging 2015; 36: 3140-3151.
33. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al., Posterior white matter disease distribution as a predictor of amyloid angiopathy. Neurology 2014; 83: 794-800.
34. Gurol ME, Viswanathan A, Gidicsin C, et al., Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 2013; 73: 529-536.
35. Takao M, Ghetti B, Murrell JR, et al., Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol 2001; 60: 1137-1152.
36. Sun SW, Song SK, Harms MP, et al., Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp Neurol 2005; 191: 77-85.
37. Collins-Praino L, Francis Y, Wiegman AF, et al., Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque burden. Acta Neuropathol Commun 2014; 2: 83.
38. Brendza RP, O'Brien C, Simmons K, et al., PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J Comp Neurol 2003; 456: 375-383.
39. Behrendt G, Baer K, Buffo A, et al., Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 2013; 61: 273-286.
40. Leuba G, Kraftsik R,. Visual cortex in Alzheimer's disease: occurrence of neuronal death and glial proliferation, and correlation with pathological hallmarks. Neurobiol Aging 1994; 15: 29-43.
41. Reddy PH,. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 2011; 1415: 136-148.
42. Pantoni L,. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701.
43. DeCarli C, Massaro J, Harvey D, et al., Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging 2005; 26: 491-510.
44. Gorelick PB, Scuteri A, Black SE, et al., Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672-2713.
45. Bennett DA, Schneider JA, Arvanitakis Z, et al., Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-1844.
46. Aizenstein HJ, Nebes RD, Saxton JA, et al., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
47. DeKosky ST, Blennow K, Ikonomovic MD Gandy S,. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 2013; 9: 192-200.
48. Crary JF, Trojanowski JQ, Schneider JA, et al., Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-766.
49. McKee AC, Stein TD, Kiernan PT, Alvarez VE,. The neuropathology of chronic traumatic encephalopathy. Brain Pathol 2015; 25: 350-364.
50. Jack CR, Jr., Petersen RC, O'Brien PC, Tangalos EG,. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183-188.
51. Raz N, Lindenberger U, Rodrigue KM, et al., Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005; 15: 1676-1689.